Latest Breaking News On - Guo jun - Page 6 : comparemela.com

Interview: China-Africa scientific collaboration contributes to Africa s anti-desertification drive, says Kenyan scholar

Interview: China-Africa scientific collaboration contributes to Africa s anti-desertification drive, says Kenyan scholar-

Nairobi areaXinhua zhou shengbinRobert gituruJomo kenyatta university of agricultureResearch centerAfrican desertification control initiativeThird taklimakan desert forumChinese academy of sciences xinhua guo junChinese academyGuo junSino africa joint research centerJomo kenyatta universityChina proposed beltRoad initiativeSecond training workshopDesertification combating

Feature: China-backed project helps Nigeria build green wall against desertification

Feature: China-backed project helps Nigeria build green wall against desertification
china.org.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from china.org.cn Daily Mail and Mail on Sunday newspapers.

Abuja federal capital territoryGuo junUmar danladi dahiruOlatunji saliuTanimu lawalBala muhammedAfrican great green wall initiativeAfrican desertification control initiativeChinese academy of sciencesDanladi dahiruChinese academyAfrican union led great green wall initiativeSahara desertGreat green wall initiative

Feature: China-backed project helps Nigeria build green wall against desertification-Xinhua

Feature: China-backed project helps Nigeria build "green wall" against desertification-

Abuja federal capital territoryUmar danladi dahiruBala muhammedGuo junTanimu lawalOlatunji saliuAfrican desertification control initiativeAfrican great green wall initiativeChinese academy of sciencesDanladi dahiruChinese academyAfrican union led great green wall initiativeSahara desert

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical.

Czech republicUnited statesFang jianminGuo junRemegen coPrnewswire remegen co ltdRemegen co ltdAmerican society of clinical oncologyNational medical products administrationSeagen incUniversity cancer hospitalAmerican societyClinical oncologyAnnual meetingObjective response rateComplete response

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on.

United statesCzech republicFang jianminGuo junRemegen coUniversity cancer hospitalAmerican society of clinical oncologyPrnewswire remegen co ltdAmerican societyClinical oncologyAnnual meetingObjective response rateComplete responseDisease control rateProgression free survivalOverall survival